{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:46:39Z","timestamp":1792233999276,"version":"4.4.0"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2019,4,1]]},"DOI":"10.1001\/jamaoncol.2018.6760","type":"journal-article","created":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T16:29:11Z","timestamp":1549556951000},"page":"523","source":"Crossref","is-referenced-by-count":331,"title":["Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines"],"prefix":"10.1001","volume":"5","author":[{"given":"Piper","family":"Nicolosi","sequence":"first","affiliation":[{"name":"Invitae Corporation, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Ledet","sequence":"additional","affiliation":[{"name":"Tulane University School of Medicine, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Yang","sequence":"additional","affiliation":[{"name":"Invitae Corporation, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Michalski","sequence":"additional","affiliation":[{"name":"Invitae Corporation, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandy","family":"Freschi","sequence":"additional","affiliation":[{"name":"Invitae Corporation, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"O\u2019Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward D.","family":"Esplin","sequence":"additional","affiliation":[{"name":"Invitae Corporation, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Nussbaum","sequence":"additional","affiliation":[{"name":"Invitae Corporation, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[{"name":"Tulane University School of Medicine, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"14","key":"coi180119r1","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi180119r2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.eururo.2014.01.003","article-title":"Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.","volume":"66","author":"Bancroft","year":"2014","journal-title":"Eur Urol"},{"issue":"18","key":"coi180119r3","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1002\/cncr.v123.18","article-title":"The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.","volume":"123","author":"Pomerantz","year":"2017","journal-title":"Cancer"},{"issue":"4","key":"coi180119r4","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1200\/JCO.2017.74.1173","article-title":"Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017.","volume":"36","author":"Giri","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi180119r5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer.","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"coi180119r6","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer.","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"6","key":"coi180119r7","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1038\/bjc.2014.30","article-title":"Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease.","volume":"110","author":"Leongamornlert","year":"2014","journal-title":"Br J Cancer"},{"issue":"5","key":"coi180119r8","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.eururo.2016.11.033","article-title":"Germline mutations in ATM and BRCA1\/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death.","volume":"71","author":"Na","year":"2017","journal-title":"Eur Urol"},{"issue":"2","key":"coi180119r9","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","article-title":"Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer.","volume":"68","author":"Castro","year":"2015","journal-title":"Eur Urol"},{"issue":"5","key":"coi180119r13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jmoldx.2015.04.009","article-title":"A systematic comparison of traditional and multigene panel testing for hereditary breast and ovarian cancer genes in more than 1000 patients.","volume":"17","author":"Lincoln","year":"2015","journal-title":"J Mol Diagn"},{"issue":"10","key":"coi180119r14","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/gim.2017.37","article-title":"Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.","volume":"19","author":"Nykamp","year":"2017","journal-title":"Genet Med"},{"issue":"1","key":"coi180119r15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/gim.2014.147","article-title":"A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment.","volume":"17","author":"Hampel","year":"2015","journal-title":"Genet Med"},{"issue":"30","key":"coi180119r16","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1200\/JCO.2017.72.3502","article-title":"Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma.","volume":"35","author":"Shindo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"20","key":"coi180119r17","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1200\/JCO.2016.69.4935","article-title":"Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores.","volume":"35","author":"Lecarpentier","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi180119r18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/ajmg.c.v178.1","article-title":"The past, present and future of service delivery in genetic counseling: keeping up in the era of precision medicine.","volume":"178","author":"Stoll","year":"2018","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"3","key":"coi180119r19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10549-016-3964-z","article-title":"A collaborative approach to cancer risk assessment services using genetic counselor extenders in a multi-system community hospital.","volume":"159","author":"Cohen","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"coi180119r20","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3389\/fonc.2016.00120","article-title":"Alternate service delivery models in cancer genetic counseling: a mini-review.","volume":"6","author":"Buchanan","year":"2016","journal-title":"Front Oncol"},{"key":"coi180119r10","unstructured":"National Comprehensive Cancer Network. Prostate cancer (version 3.2018). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf Accessed July 27, 2018."},{"key":"coi180119r11","unstructured":"National Comprehensive Cancer Network. Genetic\/familial high-risk assessment: breast and ovarian (version 2.2019). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf Accessed July 30, 2018."},{"key":"coi180119r12","unstructured":"National Comprehensive Cancer Network. Genetic\/familial high-risk assessment: colorectal (version 1.2018). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_colon.pdf Accessed July 27, 2018."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamaoncology\/article-pdf\/5\/4\/523\/17459146\/jamaoncology_nicolosi_2019_oi_180119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T22:29:41Z","timestamp":1555021781000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.6760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,1]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.6760","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4,1]]}}}